Aiwu Ruth He

Dec 19, 2023 | onclive.com | Aiwu Ruth He

Aiwu Ruth He, MD, PhD, scientific lead, Liver & Biliary Cancers, MedStar Georgetown University Hospital, discusses the evaluation of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma (HCC). The phase 3 CARES-310 trial (NCT03764293) evaluated treatment with the PD-1 inhibitor camrelizumab in combination with the VEGFR-2 inhibitor rivoceranib in patients with unresectable HCC.

Sep 25, 2023 | futuremedicine.com | Do-Youn Oh |Aiwu Ruth He |Shukui Qin |Li-Tzong Chen

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereAcknowledgmentsThis study was sponsored by AstraZeneca. We thank the participants in this study and their families, all the investigators and study site personnel, and the members of the independent data monitoring committee.